On March 29, 2023, the eighth batch of national drugs organized by the National Medical Insurance Administration and other relevant departments opened a centralized bidding. Haixi New Pharmaceutical has won the bid with the first pick of the product amlodipine atorvastatin calcium tablets (trademark name: Haihuitong®) that has passed the consistency evaluation of generic drugs.
Amlodipine atorvastatin calcium tablets (Haihuitong®) are suitable for patients who need combined treatment of amlodipine and atorvastatin; they are suitable for the treatment of hypertension, chronic stable angina pectoris, vasospasmodic angina pectoris (or variant angina pectoris), various familial or non-familial lipidemia; it can also be used to control blood pressure, lower blood lipids, stabilize plaque, and thus relieve corresponding symptoms.
The advantage of amlodipine atorvastatin calcium tablets is that they are suitable for the vast number of people with hypertension, coronary arteriosclerosis and hyperlipidemia in China. It has been changed from traditionally taking 2 tablets to taking 1 compound preparation, thus enhancing the compliance or compliance of drug use, has a significant antihypertensive effect, and effectively improving and reducing the incidence of cardiovascular events.
The winning bid for this centralized procurement of drugs is the third winning product after the company's collection of mosapris citrate tablets (Ablai®) and cinakase hydrochloride tablets (Rianto®). This will boost product sales, increase the market share of the company's products in the field of cardiovascular medicine, and have a positive impact on the company's future business performance.
